Congenital And Genetic Conditions

Congenital and genetic conditions can be inherited or caused by environmental factors and can vary from mild to severe. This section is focused on genetic and congenital disorders in children and adolescents.

Three-Year Study Finds Burosumab Improves Symptoms in Adults With X-Linked Hypophosphatemia

Three-Year Study Finds Burosumab Improves Symptoms in Adults With X-Linked Hypophosphatemia

Steven Ing, MD, Professor of Clinical Medicine in the Division of Endocrinology, Diabetes and Metabolism at The Ohio State University Wexner Medical Center, discusses three-year real-world findings from an interim analysis of the XLH Disease Monitoring Program (DMP) comparing burosumab with conventional therapy in adults with X-linked hypophosphatemia (XLH).

Sanofi’s Orphan Drug Supply Update | The CheckRare Brief Special Edition

Sanofi’s Orphan Drug Supply Update | The CheckRare Brief Special Edition

On this special edition of the CheckRare Brief, we talk with Alaa Hamed, Sanofi’s Global Head of Medical Affairs for Rare Diseases, and Maite Durrenbach, Head of Specialty Care Manufacturing and Supply at Sanofi, about the company’s current supply chain problems for some of their biological therapies.

More

Highlights from The Liver Meeting 2026 | The CheckRare Brief

In this episode, we discuss highlights from The Liver Meeting, Ultragenyx program cuts, and ANI Pharmaceuticals’ offer to buy Egetis Therapeutics.     Ultragenyx Ends Angelman Syndrome and...

3D Printed Treatment Options | The CheckRare Brief

In this episode, we discuss a new formulation of treatment for HAE, the FDA approval of Voceryq for recurrent respiratory papillomatosis, and 3D printed treatment options.       New...

Ultragenyx Gets $203M in Second Priority Review Voucher This Month | The CheckRare Brief

On this episode, we discuss the FDA approval of Enspryng for TED, the new FDA Rare Disease Framework Initiative, Ultrangenyx’s second sold PRV this month, and using AI to reduce diagnostic delays....

Ultragenyx Sells PRV for $210M | The CheckRare Brief Ep 11

In this episode, we discuss Ultragenyx’s Priority Review Voucher that sold for $210 million, the efficacy of newborn screening on MLD, and ethical considerations needed to design and conduct...

Therapies for MCT8 Deficiency and Nephrotic Syndrome Get FDA Approval | The CheckRare Brief Ep 10

On September 28th, the FDA approved Emcitate, or tiratricol, from Egetis Therapeutics. It's the first-ever treatment for MCT8 deficiency, a condition also known as Allan-Herndon-Dudley syndrome. ...

FDA CDER’s Accelerating Rare Disease Cures Program

Paz Vellanki, MD, PhD, Vice President of Clinical Development at Precision for Medicine, discusses the FDA CDER’s Accelerating Rare Disease Cures (ARC) Program.    The ARC Program was launched...

Recent Videos

Jeff’s Journey With Fabry Disease

Jeff’s Journey With Fabry Disease

Read about Jeff’s journey with Fabry disease including his diagnosis, experience living with Fabry disease, and treatment with Elfabrio. 

Congenital And Genetic Conditions